???global.info.a_carregar???
Diana Saraiva received her PhD from NOVA Medical School (Lisbon) in 2021. Her PhD research was focused on Immuno-Oncology, namely the discovery of new biomarkers and immunotherapeutic approaches in breast cancer. Diana was awarded with a Pfizer Award for Clinical Investigation (2019) and with the Scicare Health Science Accelerator Award by Novartis (2020). During her PhD, she developed collaborations with several clinicians from hospitals in Lisbon to be able to work in a translational approach. She also participated in several science dissemination activities to the general public and was tutor of PhD (1), MSc (5) and BSc (3) students. She has 8 publications, 6 of which as first author, and has several communications in renowned congresses. Diana concluded the Integrated Masters in Bioengineering, specialization in Molecular Biotechnology in 2015 in Engineering Faculty - Porto University. In her MSc thesis, developed at INEB, she worked on epithelial-to-mesenchymal transition and its correlation with tissue mechanics and cancer metastasis. She was also a researcher at Institut Pasteur, in Paris (2014), under the DENFREE European Framework, where she developed a work on genetic susceptibility to dengue disease. Additionally, she was also a research at IPATIMUP (2013), where she studied the pathogenicity of in silico-inferred mitochondrial mutations.
Ler resumo completo ↓
Identificação

Identificação pessoal

Nome completo
Diana Saraiva

Nomes de citação

  • Diana P Saraiva
  • DP Saraiva

Identificadores de autor

Ciência ID
771F-C531-0325
ORCID iD
0000-0002-7495-2288

Endereços de correio eletrónico

  • diana.saraiva@nms.unl.pt (Profissional)

Telefones

Telefone
  • 218803000 Ext.: 27028 (Profissional)

Domínios de atuação

  • Ciências Médicas e da Saúde - Medicina Básica - Imunologia
  • Ciências Médicas e da Saúde - Medicina Clínica - Oncologia
  • Ciências da Engenharia e Tecnologias - Engenharia Médica
  • Ciências Médicas e da Saúde - Biotecnologia Médica - Biomateriais

Idiomas

Idioma Conversação Leitura Escrita Compreensão Peer-review
Inglês Utilizador proficiente (C2) Utilizador proficiente (C2) Utilizador proficiente (C2) Utilizador proficiente (C2) Utilizador proficiente (C2)
Português Utilizador proficiente (C2) Utilizador proficiente (C2) Utilizador proficiente (C2) Utilizador proficiente (C2) Utilizador proficiente (C2)
Francês Utilizador independente (B1) Utilizador independente (B2) Utilizador independente (B1) Utilizador independente (B1)
Formação
Grau Classificação
2016/02/02 - 2021/02/17
Concluído
 Ciências da Saúde (Doutoramento)
Universidade Nova de Lisboa Faculdade de Ciências Médicas, Portugal
"Translating Breast Cancer Immune Features Into Biomarkers and Therapies" (TESE/DISSERTAÇÃO)
2020
Concluído
 Good Clinical Practice (Outros)
National Institute on Drug Abuse Treatment Clinical Trials Network, Estados Unidos
2017
Concluído
 Large Scale Bioinformatics for Immuno-Oncology (Outros)
Instituto Gulbenkian de Ciência, Portugal
2017
Concluído
 FlowJo (Outros)
Instituto Gulbenkian de Ciência, Portugal
2010 - 2015
Concluído
 Bioengenharia (Mestrado integrado)
Universidade do Porto Faculdade de Engenharia, Portugal
"Modeling the mechanics of EMT: effect of variations in extracellular matrix viscoelastic properties" (TESE/DISSERTAÇÃO)
 16
2010
Concluído
 Matlab (Outros)
Universidade do Porto Faculdade de Engenharia, Portugal
Percurso profissional

Outros

Categoria Profissional
Instituição de acolhimento 		Empregador
2016/06/01 - Atual PhD student Universidade Nova de Lisboa Centro de Estudos de Doenças Crónicas, Portugal
2014/09/01 - 2015/07/01 MSc student Instituto Nacional de Engenharia Biomédica, Portugal
2014/02/01 - 2014/07/01 Researcher Institut Pasteur, França
2013/02/01 - 2013/07/01 Researcher Universidade do Porto Instituto de Patologia e Imunologia Molecular, Portugal
Projetos

Bolsa

Designação Financiadores
2021/01/01 - 2022/12/31 Cracking the role and therapeutic value of novel CCR4+ low density neutrophils in breast cancer
iNOVA4Health
Investigador
iNOVA4Health
2019 - 2021 Dissecting the predictive and therapeutic value of HLA-DR-expressing cytotoxic T lymphocytes in Breast Cancer
LPCC-NRS/Terry Fox
Investigador
Liga Portuguesa Contra o Cancro
2019 - 2021 HLA-DR+ T cell subsets as biomarkers of breast cancer aggressiveness and patient response to neoadjuvant chemotherapy
Research Projects in Medicine
Investigador
José de Mello Saúde

Universidade Nova de Lisboa
2016/07/16 - 2020/03/31 Therapeutic Targets for Triple Negative Breast Cancer: Development of mono and bispecific antibodies against Notch1 ligands
PTDC/BBB-BMD/4497/2014
Investigador
Fundação para a Ciência e a Tecnologia

Outro

Designação Financiadores
2020/04/01 - 2020/06/30 Volunteer in COVID-19 Diagnostics TaskForce
COVID-19 Task Force
Outra
Universidade Nova de Lisboa Centro de Estudos de Doenças Crónicas, Portugal
Produções

Publicações

Artigo em revista
  1. Diana P Saraiva; Bruna F Correia; Rute Salvador; Nídia de Sousa; Antonio Jacinto; Sofia Braga; M Guadalupe Cabral. "Circulating Low Density Neutrophils of Breast Cancer Patients are Associated with their Worse Prognosis due to the Impairment of T cell Responses". bioRxiv (2021): https://doi.org/10.1101/2021.02.19.431986.
    Publicado • 10.1101/2021.02.19.431986
  2. Diana P Saraiva; Ana T Matias; Sofia Braga; Antonio Jacinto; M Guadalupe Cabral. "Establishment of a 3D co-culture with MDA-MB-231 breast cancer cell line and patient-derived immune cells for application in the development of immunotherapies". Frontiers in Oncology 10 (2020): https://doi.org/10.3389/fonc.2020.01543.
    Publicado • 10.3389/fonc.2020.01543
  3. Saraiva, D.P.; Jacinto, A.; Braga, S.; Cabral, M.G.. "A 3D co-culture platform of breast cancer and patient derived immune cells to analyse the response to chemotherapy and immunotherapies". Annals of Oncology 30 (2019): v781. http://dx.doi.org/10.1093/annonc/mdz268.064.
    Publicado • 10.1093/annonc/mdz268.064
  4. Saraiva, Diana P.; Jacinto, António; Borralho, Paula; Braga, Sofia; Cabral, M. Guadalupe. "HLA-DR in Cytotoxic T Lymphocytes Predicts Breast Cancer Patients' Response to Neoadjuvant Chemotherapy". Frontiers in Immunology 9 (2018): http://dx.doi.org/10.3389/fimmu.2018.02605.
    Publicado • 10.3389/fimmu.2018.02605
  5. Saraiva, D P; Jacinto, A; Braga, S; Cabral, M G. "A new biomarker of breast cancer stage and patient response to neoadjuvant chemotherapy: HLA-DR expression in cytotoxic and regulatory T cells". Annals of Oncology 29 suppl_8 (2018): http://dx.doi.org/10.1093/annonc/mdy269.118.
    Publicado • 10.1093/annonc/mdy269.118
  6. Oliveira, Marisa; Saraiva, Diana P.; Cavadas, Bruno; Fernandes, Verónica; Pedro, Nicole; Casademont, Isabelle; Koeth, Fanny; et al. "Population genetics-informed meta-analysis in seven genes associated with risk to dengue fever disease". Infection, Genetics and Evolution 62 (2018): 60-72. http://dx.doi.org/10.1016/j.meegid.2018.04.018.
    Publicado • 10.1016/j.meegid.2018.04.018
  7. Saraiva, Diana P; Guadalupe Cabral, M; Jacinto, António; Braga, Sofia. "How many diseases is triple negative breast cancer: the protagonism of the immune microenvironment". ESMO Open 2 4 (2017): e000208. http://dx.doi.org/10.1136/esmoopen-2017-000208.
    Publicado • 10.1136/esmoopen-2017-000208
  8. Bidarra, S. J.; Oliveira, P.; Rocha, S.; Saraiva, D. P.; Oliveira, C.; Barrias, C. C.. "A 3D in vitro model to explore the inter-conversion between epithelial and mesenchymal states during EMT and its reversion". Scientific Reports 6 1 (2016): http://dx.doi.org/10.1038/srep27072.
    Publicado • 10.1038/srep27072
Poster em conferência
  1. Bruna F Correia; Diana P Saraiva; Rute Salvador; Nídia de Sousa; Antonio Jacinto; Sofia Braga; M Guadalupe Cabral. "Low density neutrophils are associated with a worse prognosis in breast cancer". Trabalho apresentado em iMed Conference 12.0, 2020.
  2. Diana P Saraiva; Ana Antunes; Sofia Azeredo-Lopes; Antonio Jacinto; Sofia Braga; M Guadalupe Cabral. "HLA-DRhigh cytotoxic T cells as a validated and independent predictive biomarker of breast cancer response to treatment and as a potential therapeutic approach". Trabalho apresentado em Cancer Biology: From Basic to Translational Research, 2020.
  3. Diana P Saraiva; António Jacinto; Sofia Braga; Maria Guadalupe Cabral. "A 3D co-culture platform of breast cancer and patient derived immune cells to analyse the response to chemotherapy and immunotherapies". Trabalho apresentado em ESMO 2019, 2019.
  4. Diana P Saraiva; António Jacinto; Sofia Braga; Maria Guadalupe Cabral. "HLA-DR in Cytotoxic T Lymphocytes Predicts Breast Cancer Patients' Response to Neoadjuvant Chemotherapy". Trabalho apresentado em NOVA Science Day, 2019.
  5. Diana P Saraiva; Sofia Braga; António Jacinto; Maria Guadalupe Cabral. "Validation of the predictive value of HLA- DR+ Cytotoxic T Lymphocytes in the response of Breast Cancer patients’ to Neoadjuvant Chemotherapy". Trabalho apresentado em 2nd Human and Translational Immunology Conference, 2019.
  6. Diana P Saraiva; Sofia Braga; António Jacinto; Maria Guadalupe Cabral. "A new biomarker of breast cancer stage and patient response to neoadjuvant chemotherapy: HLA-DR expression in cytotoxic and regulatory T cells". Trabalho apresentado em ESMO 2018, 2018.
  7. Diana P Saraiva; Sofia Braga; António Jacinto; Maria Guadalupe Cabral. "HLA-DR in cytotoxic and regulatory T cells dictates breast cancer aggressiveness and patient response to neoadjuvant chemotherapy". Trabalho apresentado em 5th European Congress of Immunology, 2018.
  8. Diana P Saraiva; Sofia Braga; António Jacinto; Maria Guadalupe Cabral. "HLA-DR in cytotoxic and regulatory T cells dictates breast cancer aggressiveness and patient response to neoadjuvant chemotherapy". Trabalho apresentado em XLIV Meeting of Portuguese Society of Immunology, 2018.
  9. Diana P Saraiva; Sofia Braga; António Jacinto; Maria Guadalupe Cabral. "HLA-DR in cytotoxic T cells predicts breast cancer patients’ response to neoadjuvant chemotherapy". Trabalho apresentado em 2nd NMS Symposium, 2018.
  10. Diana P Saraiva; Sofia Braga; António Jacinto; Maria Guadalupe Cabral. "Establishment of a prospective study to unveil the predictive value of breast cancer immune features in the response to neoadjuvant chemotherapy". Trabalho apresentado em 4th Conference on Translational Medicine on Pathogenesis and Therapy of Immune-mediated diseases, 2017.
  11. Diana P Saraiva; Sofia Braga; António Jacinto; Maria Guadalupe Cabral. "Establishment of a prospective study to unveil the predictive value of breast cancer immune features in the response to neoadjuvant chemotherapy". Trabalho apresentado em iNOVA4Health Symposium on Inflammation, 2017.
  12. Diana P Saraiva; Veronica Fernandes; Marisa Oliveira; O Anunciação; I Casademont; Anavaj Sakuntabhai; Luisa Pereira. "The global distributions of alleles associated with dengue infection and design of a predictive genetic risk model". Trabalho apresentado em 4th I3S Meeting, 2014.
Tese / Dissertação
  1. Diana P Saraiva. "Translating Breast Cancer Immune Features Into Biomarkers and Therapies". Doutoramento, Universidade Nova de Lisboa Faculdade de Ciências Médicas, 2020.
  2. Saraiva, Diana. "Modelling the mechanics of EMT: effect of variations in extracellular matrix viscoelastic properties". Mestrado, Universidade do Porto Faculdade de Engenharia, 2015. https://repositorio-aberto.up.pt/bitstream/10216/89799/2/35909.pdf.
Atividades

Apresentação oral de trabalho

Título da apresentação Nome do evento
Anfitrião (Local do evento)
2020/10/30 Translating Breast Cancer Immune Features Into Biomarkers And Therapies CEDOC Seminar
Faculdade de Ciências Médicas Universidade NOVA de Lisboa
2020/01/14 Translating breast cancer immune features into biomarkers and therapies Jornadas Médicas
Instituto CUF de Oncologia
2019/01/24 HLA-DR in cytotoxic T lymphocytes predicts breast cancer patients’ response to neoadjuvant chemotherapy Unidade de Investigação em Patologia Molecular (UIPM) seminar cycles
Instituto Português de Oncologia de Lisboa
2018/11/23 HLA-DR in cytotoxic T cells as a predictor of breast cancer patients’ response to treatment CEDOC Seminars
Universidade Nova de Lisboa Faculdade de Ciências Médicas
2018/10/19 HLA-DR in cytotoxic T lymphocytes is a predictive factor of breast cancer patients’ response to neoadjuvant chemotherapy 2nd NOVA Medical School Symposium - Translational Science and Healthcare Application at NOVA
NOVA Medical School
2018/05/03 HLA-DR in cytotoxic and regulatory T cells dictates breast cancer aggressiveness and patient response to neoadjuvant chemotherapy 25th Porto Cancer Meeting
i3S
2018/01/30 Translating Breast Cancer Immune Features into putative Biomarkers: HLA-DR in Cytotoxic T Lymphocytes Predicts the Response to Neoadjuvant Chemotherapy. 3th World PreClinical Congress
CHI - Cambridge Innovation Institute
2017/09/24 Translating breast cancer immune features into target therapies CEDOC Retreat
Universidade Nova de Lisboa Faculdade de Ciências Médicas

Organização de evento

Nome do evento
Tipo de evento (Tipo de participação) 		Instituição / Organização
2018/10/12 - 2018/10/14 CEDOC PhD Retreat (2018/10/12 - 2018/10/14)
Congresso (Coorganizador)
 Universidade Nova de Lisboa Centro de Estudos de Doenças Crónicas, Portugal
2018/06/30 - 2018/06/30 CEDOC Open Day (2016/06/30)
Outro (Coorganizador)
 Universidade Nova de Lisboa Centro de Estudos de Doenças Crónicas, Portugal

Participação em evento

Descrição da atividade
Tipo de evento 		Nome do evento
Instituição / Organização
2020/02/29 - 2020/02/29 CEDOC - Lysocil Open Day
Outro
Universidade Nova de Lisboa Centro de Estudos de Doenças Crónicas, Portugal
2016/10/29 - 2016/10/29 CEDOC Open Day
Outro
Universidade Nova de Lisboa Centro de Estudos de Doenças Crónicas, Portugal

Arbitragem científica em revista

Nome da revista (ISSN) Editora
2018 - 2018 OncoImmunology Taylor and Francis

Curso / Disciplina lecionado

Disciplina Curso (Tipo) Instituição / Organização
2019 - 2020 Clinical and Translational Oncology MSc Nova Biomedical Research Universidade Nova de Lisboa Faculdade de Ciências Médicas, Portugal
2017 - 2018 Clinical Oncology MSc Oncobiology - Molecular Mechanisms in Cancer Universidade do Algarve, Portugal

Entrevista (jornal / revista)

Descrição da atividade Jornal / Forum
2019/11/15 Prémios Pfizer: projetos vencedores contribuem para a investigação sobre o autismo e o cancro da mama News Farma
2019/11/14 "O que nos dizem um gene sobre o autismo e os linfócitos sobre o cancro da mama?" Publico
2019/11/14 Pfizer 2019 distingue investigação sobre autismo e cancro da mama Noticias Ao Minuto
2019/11/14 Prémios Pfizer 2019 para investigação sobre autismo e cancro da mama Diário de Notícias
2019/05 Novas Fronteiras no Cancro da Mama Frontal
2019/03/18 Análises detetam se doentes com cancro da mama vão ter boa resposta à quimioterapia Diário de Notícias

Membro de associação

Nome da associação Tipo de participação
2018 - Atual Portuguese Society of Immunology - SPI Member
2017 - 2020 European Society of Medical Oncology - ESMO Member
2016 - 2017 Portuguese Society of Developmental Biology - SPBD Member

Membro de comissão

Descrição da atividade
Tipo de participação 		Instituição / Organização
2017 - 2018 CEDOC PhD Committee
Membro
 Universidade Nova de Lisboa Centro de Estudos de Doenças Crónicas, Portugal

Tutoria

Tópico Nome do aluno
2020/09 - Atual MSc Thesis - Circulatory Biomarkers of Melanoma Metastasis José Maximino
2019/12 - Atual PhD Thesis - Dissecting the predictive and therapeutic value of HLA-DR-expressing cytotoxic T lymphocytes in Breast Cancer Rute Salvador
2019/07 - 2021/01 MSc thesis - Unveiling the clinical relevance of low density neutrophils in Breast Cancer patients Bruna Correia
2020/02 - 2020/03 Unravelling the biomolecular mechanisms of anti-tumour properties of HLA-DR-expressing cytotoxic T cells in breast cancer (MSc) Jéssica Kamiki
2019/04 - 2019/05 Assessing HLA-DR+ cytotoxic t lymphocytes cytotoxicity to MCF-7 tumor cell line in 3D co-cultures by flow cytometry (MSc) Nuno Silva
2018/06 - 2018/07 BSc student internship Yen Ting
2018/05 - 2018/06 Immuno-markers and Breast Cancer (MSc) Sarah Dias
2017/06 - 2017/07 BSc student internship Fernanda M
2017/01 - 2017/07 BSc student internship Margarida Duarte
Distinções

Prémio

2020 SciCare - Novartis Health Science Accelerator
Novartis Farma SA, Portugal
2019 Pfizer Award Clinical Investigation

Outra distinção

2016 PhD Fellowship
Fundação para a Ciência e a Tecnologia, Portugal
2014 Scholarship
Institut Pasteur, França